WallStreetZenWallStreetZen

NASDAQ: INSM
Insmed Inc Stock

$27.96+0.39 (+1.41%)
Updated Dec 8, 2023
INSM Price
$27.96
Fair Value Price
$35.07
Market Cap
$4.00B
52 Week Low
$16.04
52 Week High
$28.32
P/E
-5.29x
P/B
-13.82x
P/S
12.85x
PEG
N/A
Dividend Yield
N/A
Revenue
$280.82M
Earnings
-$723.63M
Gross Margin
78.6%
Operating Margin
-229.54%
Profit Margin
-257.7%
Debt to Equity
-5.58
Operating Cash Flow
-$509M
Beta
1.37
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

INSM Overview

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how INSM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

INSM ($27.96) is undervalued by 20.26% relative to our estimate of its Fair Value price of $35.07 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
INSM ($27.96) is significantly undervalued by 20.26% relative to our estimate of its Fair Value price of $35.07 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
INSM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more INSM due diligence checks available for Premium users.

Be the first to know about important INSM news, forecast changes, insider trades & much more!

INSM News

Valuation

INSM fair value

Fair Value of INSM stock based on Discounted Cash Flow (DCF)
Price
$27.96
Fair Value
$35.07
Undervalued by
20.26%
INSM ($27.96) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
INSM ($27.96) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
INSM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

INSM price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-5.29x
Industry
11.7x
Market
31.32x

INSM price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-13.82x
Industry
5.42x

INSM's financial health

Profit margin

Revenue
$79.1M
Net Income
-$158.9M
Profit Margin
-201%
INSM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
INSM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$1.3B
Liabilities
$1.6B
Debt to equity
-5.58
INSM's short-term assets ($926.58M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INSM's long-term liabilities ($1.42B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INSM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
INSM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$136.3M
Investing
$7.1M
Financing
$1.2M
INSM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

INSM vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
INSM$4.00B+1.41%-5.29x-13.82x
MRTX$3.96B-0.35%-4.62x4.19x
MDGL$4.11B-11.58%-10.83x184.85x
NUVL$4.43B-0.24%-34.64x11.18x
BPMC$4.50B+0.27%-8.05x22.20x

Insmed Stock FAQ

What is Insmed's quote symbol?

(NASDAQ: INSM) Insmed trades on the NASDAQ under the ticker symbol INSM. Insmed stock quotes can also be displayed as NASDAQ: INSM.

If you're new to stock investing, here's how to buy Insmed stock.

What is the 52 week high and low for Insmed (NASDAQ: INSM)?

(NASDAQ: INSM) Insmed's 52-week high was $28.32, and its 52-week low was $16.04. It is currently -1.27% from its 52-week high and 74.31% from its 52-week low.

How much is Insmed stock worth today?

(NASDAQ: INSM) Insmed currently has 143,062,065 outstanding shares. With Insmed stock trading at $27.96 per share, the total value of Insmed stock (market capitalization) is $4.00B.

Insmed stock was originally listed at a price of $164.80 in Jun 1, 2000. If you had invested in Insmed stock at $164.80, your return over the last 23 years would have been -83.03%, for an annualized return of -7.42% (not including any dividends or dividend reinvestments).

How much is Insmed's stock price per share?

(NASDAQ: INSM) Insmed stock price per share is $27.96 today (as of Dec 8, 2023).

What is Insmed's Market Cap?

(NASDAQ: INSM) Insmed's market cap is $4.00B, as of Dec 10, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Insmed's market cap is calculated by multiplying INSM's current stock price of $27.96 by INSM's total outstanding shares of 143,062,065.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.